ALK
ALK tyrosine kinase receptor
As of the edition of 20 October 2026, ALK (ALK tyrosine kinase receptor, UniProt Q9UM73) has 17 drugs tested at it and 12 companies on the list, 3 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9UM73
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 80
- Disease areas
- Cancer; Lungs and airways; Blood and lymph; Immune system; Nervous system; Digestive system; Urinary and reproductive; Pregnancy and women's health
- Registered trials of its drugs
- 369
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 7 |
| Active | 3 |
| Went quiet | 3 |
| Stopped | 1 |
| Status not established | 3 |
| Total | 17 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Crizotinib | Marketed | Phase 4 | Ends 2029 |
| Alectinib | Marketed | Phase 4 | Ends 2031 |
| Lorlatinib | Marketed | Phase 4 | Ends 2038 |
| Ceritinib | Marketed | Phase 4 | Ends 2032 |
| Ensartinib | Marketed | Phase 4 | Ends 2037 |
| Brigatinib | Marketed | Phase 3 | Ends 2035 |
| Entrectinib | Marketed | Phase 4 | Ends 2037 |
| Iruplinalkib | Active | Phase 2 | none listed |
| WX-0593 | Status not established | Phase 3 | none listed |
| Neladalkib | Active | Phase 3 | none listed |
| APG-2449 | Active | Phase 1 | none listed |
| ASP-3026 | Went quiet | Phase 1 | none listed |
12 of 17 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 3 |
| Engaged | 4 |
| Undetermined | 2 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Bristol Myers Squibb | Route A |
| Takeda | Route B |
The other 9 companies at ALK
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at ALK, ranked, with the facts behind eachRequest access. Nothing is shown until you do.